Compare EVO & PGY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EVO | PGY |
|---|---|---|
| Founded | 1993 | 2016 |
| Country | Germany | United States |
| Employees | 4553 | 511 |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | N/A | N/A |
| Metric | EVO | PGY |
|---|---|---|
| Price | $3.07 | $14.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $7.00 | ★ $34.50 |
| AVG Volume (30 Days) | 47.1K | ★ 3.6M |
| Earning Date | 04-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.37 | $14.27 |
| Revenue Next Year | $10.05 | $14.39 |
| P/E Ratio | ★ N/A | $13.54 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.31 | $10.40 |
| 52 Week High | $4.42 | $44.99 |
| Indicator | EVO | PGY |
|---|---|---|
| Relative Strength Index (RSI) | 56.03 | 59.89 |
| Support Level | $2.88 | $10.78 |
| Resistance Level | $3.75 | $15.57 |
| Average True Range (ATR) | 0.07 | 0.83 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 89.58 | 90.27 |
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
Pagaya Technologies Ltd is a product-focused technology company. It uses machine learning, a vast data network, and an AI-driven approach to offer comprehensive consumer credit and residential real estate products for its partners, their customers, and investors. Its suite of products includes Decline Monetization, Dual Look, First Look, Affiliate Optimizer Engine, Direct Marketing Engine, and FastPass, providing lenders with an AI-powered credit and acquisition ecosystem that helps them approve more borrowers, capture more demand, and grow without adding risk. Geographically, the company generates maximum revenue from its business in the United States.